top of page
Qubigen to Attend Bio-IT World Conference & Expo 2026 in Boston
Qubigen will have an active presence at the Bio-IT World Conference & Expo 2026 in Boston, taking place May 19–21, 2026. Qubigen is pleased to announce that Eric Hayes, External Business Development, will be attending with a focus on forging institutional partnerships across the AI-in-Pharma ecosystem. A Global Hub for Bio-IT Innovation and AI-Driven Drug Discovery Bio-IT World is a leading global event bringing together leaders from biotechnology, pharmaceuticals, healthcare
Apr 212 min read
Qubigen and University of Melbourne Secure Federal AEA Grant to Advance AI-Driven Drug Design
Qubigen is proud to announce the successful award of an Australian Government Australia’s Economic Accelerator (AEA) Ignite grant in partnership with the University of Melbourne, supporting a ground-breaking project at the intersection of artificial intelligence and medical science. The project, “AI-Driven Drug Discovery for Next-Generation STING Inhibitors” has been awarded $496,348 in federal funding and will accelerate the development of novel therapeutics for neuroinflamm
Feb 132 min read
One Year of Qubigen: From Federated AI Vision to Scalable Drug Design Reality
As Qubigen approaches the end of 2025, we mark an important milestone: our first year of operation. In just over twelve months, Qubigen has evolved from an innovative idea into a validated, capital-efficient drug design platform, demonstrating that secure, Federated AI can deliver real scientific progress, commercial traction, and scalable value across the life sciences ecosystem. This first year has been defined by three converging forces: strong technical performance, globa
Dec 23, 20254 min read
bottom of page